Apimeds Pharmaceuticals US closed at $2.92 on Nov 4, down 1.68%, 98.3% below its highest close since May 9. Volume of 11.2K shares was 0.01× its 20-day average (below normal).
Split-adjusted performance: -59.0% over one month, -85.0% over six months.
Short interest was 73.0K shares at the Oct 15 settlement, down 8.2% from the prior report (0.9% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| APUSApimeds Pharmaceuticals US | $2.92 | −1.68% | −85.0% | — | — | — | $4.4M | |
| TCRTAlaunos Therapeutics | $1.80 | −3.23% | −31.6% | — | — | — | $4.6M | Compare |
| DRMADermata Therapeutics | $0.8548 | +0.72% | −32.7% | — | — | — | $4.2M | Compare |
| TRAWTraws Pharma | $0.2686 | −11.06% | −84.2% | −100.0% | — | — | $4.1M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
| SKYESkye Bioscience | $1.14 | −6.56% | −83.3% | — | — | — | $5.0M | Compare |
| IMNNImunon | $0.9070 | +0.78% | −66.5% | — | — | — | $5.1M | Compare |
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
